{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.54","value":"11.5"},{"groupId":"OG001","spread":"3.54","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"PROMIS measures capability of physical functioning, with questions related to daily activities. Participants 8-17 years complete a self-report of physical function in the upper extremity or lower extremity (mobility), depending on the location of the PN. The recall period is 7 days. All PROMIS items are answered on a Likert scale with responses ranging from 1 to 5, with higher scores representing higher physical functioning in the upper extremities. The total raw score will be calculated as the sum of the individual item responses at a given visit (total raw scale range 8-40). The total raw scores for the measure will be converted to T-scores using the applicable score conversion table in the user manual and scoring instructions (PROMIS, 2023) ranging from 10 to 57 for self-report, and 13 to 55 for parent proxy with higher scores representing higher reported physical functioning and better outcomes. A T-score of 50 indicates the population mean with a standard deviation of 10.","dispersionType":"Standard Deviation","groups":[{"description":"Patients self-reported results aged 8 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901) - Self-Report"},{"description":"Patients parent proxy results aged 5 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901) - Parent Proxy"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set eligible for the instrument at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months","title":"Change From Baseline in Physical Function Status as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) at Cycle 13: Pediatric v2.0 Upper Extremities 8a.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"T-score"}